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(AML), subtype M4 with 40% BM blasts and cytogenetic 
examination showed clonal evolution by the appearance 
of additional numerical aberrations in addition to the ring 
chromosome [46,XY,r(1),+8,–21/45,XY,r(1),+8,–21,–22/46,
XY]. Intensive chemotherapy and radiotherapy was ap-
plied to induce remission in preparation for allogeneic 
bone marrow transplantation (BMT) from the patient’s 
HLA-compatible son. After BMT, complete remission was 
clinically, hematologically and cytogenetically (normal 
male karyotype) confi rmed. A complete hematopoietic 
chimerism was demonstrated. A relapse in January 1997 
was successfully treated using donor lymphocyte infu-
sion and donor peripheral blood stem cells (PB-SC) in 
combination with GM-CSF as immunostimulating agent 
in April 1997, and the patient’s clinical condition remained 
stable as of January 2005. This is an interesting case of a 
patient with AML secondary to MDS. With the ring chro-
mosome 1 we also describe a rare cytogenetic abnormal-
ity that predicted the poor prognosis of the patient, but 
the patient could be cured by adoptive immunotherapy 
and the application of donor’s PB-SC. This case confi rms 
the value of cytogenetic analysis in characterizing the 
malignant clone in hematological neoplasias, the impor-
tance of controlling the quality of an induced remission 
and of the detection of a progress of the disease. 
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 Abstract 
 Karyotypic evolution is a well-known phenomenon in pa-
tients with malignant hematological disorders during dis-
ease progression. We describe a 50-year-old male patient 
who had originally presented with pancytopenia in Octo-
ber 1992. The diagnosis of a myelodysplastic syndrome 
(MDS) FAB subtype RAEB-t was established in April 1993 
by histological bone marrow (BM) examination, and ther-
apy with low-dose cytosine arabinoside was initiated. In 
a phase of partial hematological remission, cytogenetic 
assessment in August 1993 revealed a ring chromosome 
1 in 13 of 21 metaphases beside BM cells with normal 
karyotypes [46,XY,r(1)(p35q31)/46,XY]. One month later, 
the patient progressed to an acute myeloid leukemia 
 Received: April 11, 2005 
 Accepted after revision: September 10, 2005 
 Helga Schmetzer, PhD
Klinikum Grosshadern, Medical Department III
Marchioninistrasse 15, DE–81377 Munich (Germany)
Tel. +49 89 7095 6135 or 3137, Fax +49 89 7095 6137
E-Mail Helga.Schmetzer@med.uni-muenchen.de 
 © 2006 S. Karger AG, Basel
0001–5792/06/1162–0131$23.50/0 
 Accessible online at:
www.karger.com/aha 
 Thomas Duell and Brigitte Poleck-Dehlin contributed equally to this 
publication. 
 Duell  et al.
 
 Acta Haematol 2006;116:131–136 132
 Introduction 
 Cytogenetic abnormalities are known to occur in bone 
marrow (BM) cells in about 50% of patients with myelo-
dysplastic syndrome (MDS) and acute myeloid leukemia 
(AML)  [1–3] . Clonal karyotype evolution is a well-known 
phenomenon in these patients, often preceding a clinical 
progression of the disease. This is why cytogenetic ex-
aminations make a valuable tool to estimate the progno-
sis; usually, patients with certain cytogenetic markers or 
with a complex karyotype or with a new arising marker 
in the course of the disease have a worse prognosis than 
those without a cytogenetic abnormality  [1, 4] . Ring chro-
mosomes are genetic abnormalities occurring in leukemic 
and other neoplastic cells and are often related to a poor-
er prognosis  [5, 6] . Ring chromosomes have been de-
scribed in patients with MDS  [7] but so far no ring chro-
mosome 1. 
 Despite the advent of new therapeutic agents, the prog-
nosis of an MDS and secondary AML is still very poor 
 [8] . Generally, secondary leukemias are harder to treat 
than primary malignancies. Bone marrow transplanta-
tion (BMT) is regarded as the only curative treatment for 
patients younger than 60 years  [9] . We report an MDS 
(RAEB-t subtype) patient who had presented with a ring 
chromosome 1, followed by a clonal evolution in BM 
cells, who had an early progress which could be treated 
by BMT and achieved a long-term remission after a re-
lapse by adoptive immunotherapy using donor lympho-
cyte infusion (DLI) and donor peripheral blood stem cells 
(PB-SC). 
 Case Report  
 A 50-year-old male patient was admitted to our facility in April 
1993 for a medical workup after outpatient blood examinations had 
shown persistent asymptomatic pancytopenia since October 1992. 
The PB revealed pancytopenias with 28 !109/l leukocytes, 11 g/dl 
hemoglobin, 68 !109/l thrombocytes and 1% blast cells. BM ex-
amination revealed a blast count of 29 with 60% of those cells being 
peroxidase positive and 50% of them being esterase positive. 
Ringed sideroblasts or Auer rods were not detectable. According to 
the French-American-British (FAB) classifi cation ( table 1 )  [10] , the 
disease was rated as an MDS subtype RAEB-t with transition into 
an AML. From May to July 1993, the patient received low-dose 
cytosine arabinoside chemotherapy. In August 1993, the patient 
was found to have gone into partial remission with a BM blast count 
of 10%. Cytogenetic analysis revealed a ring chromosome 1 in 13 
of 21 metaphases indicating the persistence of clonal, leukemic 
cells: (46,XY,r(1)(p35q31)[13]/46,XY[8]) ( fi g. 1 ). Only 1 month 
later, the disease progressed to an AML, subtype M4 (myelomono-
cytic leukemia) with a BM blast count of 39% and monocytoid-dif-
ferentiated blasts (CD14+, CD33+, CD13+, HLA-Dr+) detectable 
by fl ow cytometry. Cytogenetically, disease progression was also 
indicated by clonal evolution, which consisted of additional nu-
meric aberrations of chromosomes 2, 21 and 22 (45,XY,r(1)
(p35q31),+8,–21,–22[7]/r(1)(p35q31),+8,–21[10]/46,XY[4]). 
 The origin of the ring chromosome could be identifi ed by G 
banding. The rings were homogeneous in structure. In  fi gure 1 , a 
small fragment of chromosome 1 can be seen demonstrating that 
not the whole genetic material was included in the ring, but a frag-
ment (q24–43) was deleted. These small q-arm fragments could be 
seen in the preparation of August but not in that of September 2003 
and might have been lost during the preparation. 
 The patient received intensive chemotherapy according to the 
sHAM protocol (hexamethylenamine, Adriamycin, melphalan, 
methotrexate) and total body irradiation to prepare for allogeneic 
transplant in December 1993, using his son’s HLA-compatible BM. 
A complete chimerism was established with cells of his son charac-
terized by a phosphoglucomutase 1 (PGM1) type a3a1 isoenzyme 
type (the patient’s PGM1 type was a1a1)  [11] . The a3a1 donor 
PGM1 type was demonstrable at 14 different time points between 
April 1994 and September 1998 in several cellular fractions (gran-
ulocytes, platelets, erythrocytes or lymphocytes) obtained from PB 
or BM of the patient (data not shown). In January 1997 a relapse 
of the patient’s AML was noted on BM examination with a BM 
blast cell count of 18% and a PB blast cell count of 2%. The pres-
ence of donor cells in the PB was demonstrable by the PGM1 donor 
isoenzyme type a3a1. Therefore, the patient could be treated with 
a DLI-based therapy in combination with LD-AraC and PB-SC 
without immunosuppressive therapy and immunostimulation with 
GM-CSF in April 1997 using his son’s lymphocytes. After DLI 
therapy he developed an acute graft versus host reaction of the skin 
(grade 3) and the intestine; however, he achieved a second remis-
sion which has been stable as of January 2005. 
 The clinical course of the patient was complicated by several 
transplantation/therapy-associated diseases like EBV-associated 
pleural polyserositis, a cataract, glaucoma, and stem cell transplan-
tation (SCT)-associated keratoconjunctivitis. Moreover, the pa-
tient suffered from herpes infection, diabetes type 2 and osteopo-
rosis. 
 Material and Methods 
 Morphological Examinations 
 Cytological and cytochemical examinations of the BM cells 
were performed by staining the cell smears with Pappenheim solu-
tion; peroxidase (POX; rendering yellow stain to granulopoietic 
cells except myeloblasts) and esterase reactions (macrophages and 
monocytes strongly react positively) were performed according to 
standard procedures  [10, 12] . 
 Immunophenotyping 
 Flow-cytometric analysis was employed to determine lineage 
and maturation of the surface markers. Mononuclear BM cells were 
incubated with a panel of monoclonal antibodies conjugated with 
fl uorescent dyes  [13] . Subsequent analysis was done to determine 
the proportions of cells and the blast phenotype, according to the 
manufacturer’s instruction (Cytoron Absolute, Ortho Diagnostic 
Systems). 
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 Cytogenetics 
 Cytogenetic techniques were facilitated by incubation of un-
separated BM cells for 48 h at 37  °  C. Metaphase chromosome anal-
ysis and Giemsa banding of chromosomes were executed according 
to standard staining procedures  [14] . 
 Discussion 
 MDS are disorders characterized by hematopoietic ab-
normalities involving the clonal hematopoietic progeni-
tor cells resulting in uncontrolled proliferation, differen-
tiation or maturation of hematopoietic cells  [1, 3, 4] . The 
Table 1. Patient’s course of the disease
Date Diagnosis Clinical stage Therapy BM blasts
%
Cytogenetics
October 1992 pancytopenia
April 1993 MDS (RAEB-t) diagnosis LD-AraC
May to September 1993
29 not available
August 1993 MDS-PR 10 46,XY,r(1)(p35q31)[13]/46,XY[8]
September 1993 sAML-M4 AML diagnosis 39 45,XY,r(1)(p35q31),+8,–21,
–22/46XY,r(1)(p35q31),+8,
–21[10]/46,XY[4]
sHAM/Endoxan/TBI
September to December 
1993
November 1993 sAML-M4 AML pers allogeneic SCT
December 1993
<2
April 1994 sAML AML-CR <5 46,XY[19–32]
(5 different analyses)
September 1996 cataract and glaucoma surgery <5
December 1996 sAML AML-CR
January 1997 sAML AML relapse af-
ter SCT
18
LD-AraC
January to February 1997
aGvH
GM-CSF, DLI, predniso-
lone, cyclosporine
February 1997
May to October 
1997
osteoporosis AML-CR Aredia <5 46,XY[23–28]
(2 different analyses between May 
and October 1997)
aGvH
June 1999 EBV-associated polyse-
rositis, pleural and peri-
cardial effusion 
Cidofovir
June 1999 to May 2000
August 1999 diabetes (subtype 2) Euglucon
August 1999
May 2000 herpes zoster
retinal detachment
October 2003
May 2004 SCT-associated
keratoconjunctivitis
January 2005 AML-CR
The patient’s disease with diagnosis, treatment measures and outcome is demonstrated as related to time. The course of the disease 
can be seen between October 1992, the diagnosis of pancytopenia, and January 2005, after treatment of AML with BMT, of AML re-
lapse with DLI and of concomitant diseases. The patient is still in remission of AML. PR = Partial remission; CR = complete remission; 
sAML = secondary AML; aGvH = acute graft versus host disease; TBI = total body irradiation; pers = persisting disease.
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only potentially curative treatment for these patients is 
allogeneic hematopoietic SCT  [15, 16] . Relapses after 
transplantation, however, occur and are due to a reemerg-
ing of the malignant cell clones, regularly detectable by 
an increase of blast cells in PB or BM, reduction of blast 
phenotypes and/or clonal markers  [4, 17–19] . Isoenzyme 
studies are good means for follow-up analyses of chime-
rism after SCT. The detection of donor cells in a relapsed 
patient allows a DLI therapy without preliminary immu-
nosuppression  [11, 20] . Relapses after SCT occur and can 
be successfully treated by DLI-based therapy as described 
by others and us  [21–23] , although the details of DLI-
based treatment of a relapse post-SCT in MDS (e.g. with 
purifi ed donor T cells or pooled lymphocytes prior che-
motherapy) remain to be established  [21, 24] . In our case 
a stable remission could be established by DLI therapy 
pointing to the crucial and impressive therapeutic effi cacy 
of donor lymphocytes in eradicating tumor burden and 
establishing a stable remission as already shown in a small 
group of patients treated in a DLI-based pilot study  [23] . 
 The clinical course of the patient was complicated by 
several SCT and/or graft- versus- host disease-associated 
side effects; ocular abnormalities like cataracts, kerato-
conjunctivitis or glaucoma due to microvascular lesions 
are observed especially in patients conditioned with total 
body irradiation and cyclosporin A and are more often 
seen in patients with chronic graft versus host disease 
 [25–27] . Loss of bone mineral density resulting in osteo-
 Fig. 1. Karyotype analysis was performed by Giesma banding of 
metaphases obtained from uncultured BM cells in August 1993. In 
13 of 21 metaphases a ring chromosome 1 could be detected. The 
rings resulting from a break and fusion at q24 were homogeneous 
in structure. The remaining genetic material (q24–43) could be 
seen in some preparations. 
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porosis as well as the development of diabetes mellitus 
type 2 could be a late effect of SCT  [28–31] . EBV or her-
pes virus infections are still complications in patients af-
ter SCT and are often responsible for morbidity and mor-
tality after SCT  [32, 33] . Possibly these infections could 
be responsible for pleural or pericardial effusions as ob-
served in our patient  [34] . Effective prophylactic or pre-
emptive treatment strategies and infection controls after 
transplantation could help to avoid transplant-related 
problems  [33, 35] . 
 Independent of FAB types cytogenetics contributes 
important diagnostic and prognostic data in AML and 
MDS which give clues for therapeutic decisions  [17, 36, 
37] . Ring chromosomes are rare cytogenetic fi ndings in 
MDS. Usually they appear in cases with a complex karyo-
type and are associated with a poor prognosis  [6, 7, 38] . 
Moreover it was shown that clones containing ring chro-
mosomes might be more resistant to chemotherapy than 
other cytogenetically abnormal clones  [7] . It could be 
demonstrated that the emergence of ring chromosomes 
correlates well with worsening pancytopenia or transfu-
sion requirements for the patient  [38] . In univariate 
analyses Sole et al.  [39]  could demonstrate that aberra-
tions at the q-arm of chromosome 1 were associated with 
an unfavorable prognosis for MDS patients, making pa-
tients presenting with such abnormalities good candi-
dates for a more aggressive, curative therapeutic regi-
men like BMT. Detailed information about the effect of 
deletions of parts of chromosome 1 on the outcome of 
MDS patients is still missing. 
 We describe a case of MDS and secondary AML in a 
relatively young man with a favorable clinical course, al-
though the cytogenetic fi ndings of a ring chromosome and 
a complex aberrant karyotype would normally indicate a 
rather poor prognosis  [1, 2, 4, 36, 37] . Also, there was 
rapid progression to a secondary acute leukemia, which 
is often harder to treat than the primary leukemia and has 
a very short survival time. Despite concomitant SCT-re-
lated problems, allogeneic BMT and the DLI treatment 
for a relapse proved to be a successful therapy, with the 
patient being in a stable condition for more than 7 years 
after the initial diagnosis. 
 To our knowledge ring chromosomes of chromosome 1 
were not described in MDS. The clinical course of the pa-
tient demonstrates that this ring chromosome 1 contrib-
uted to the further clinical course of the disease: the clonal 
evolution and the fast progression, which could only be 
cured by BMT with an allogeneic transplant. The relevance 
of a ring chromosome has not been established; more data 
need to be collected for establishing the role and impact of 
a ring chromosome in a patient with MDS and AML. 
 This case illustrates the already well-established im-
portance of performing cytogenetic examinations addi-
tionally to histomorphological techniques in patients 
with MDS and AML  [4, 16, 17, 40] . 
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